Cargando…

PIK3CA Mutation as Potential Poor Prognostic Marker in Asian Female Breast Cancer Patients Who Received Adjuvant Chemotherapy

Background: The prognostic relevance of the PIK3CA mutation together with PD-L1, c-Met, and mismatch repair deficiency (dMMR) have not been fully investigated in Asian women with breast cancer (BC) who have undergone postoperative adjuvant chemotherapy. Methods: We analyzed PIK3CA mutations via pept...

Descripción completa

Detalles Bibliográficos
Autores principales: Cho, Yoon Ah, Ko, Seung Yeon, Suh, Yong Joon, Kim, Sanghwa, Park, Jung Ho, Park, Hye-Rim, Seo, Jinwon, Choi, Hyo Geun, Kang, Ho Suk, Lim, Hyun, Park, Ha Young, Kwon, Mi Jung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9140087/
https://www.ncbi.nlm.nih.gov/pubmed/35621626
http://dx.doi.org/10.3390/curroncol29050236
_version_ 1784715013069471744
author Cho, Yoon Ah
Ko, Seung Yeon
Suh, Yong Joon
Kim, Sanghwa
Park, Jung Ho
Park, Hye-Rim
Seo, Jinwon
Choi, Hyo Geun
Kang, Ho Suk
Lim, Hyun
Park, Ha Young
Kwon, Mi Jung
author_facet Cho, Yoon Ah
Ko, Seung Yeon
Suh, Yong Joon
Kim, Sanghwa
Park, Jung Ho
Park, Hye-Rim
Seo, Jinwon
Choi, Hyo Geun
Kang, Ho Suk
Lim, Hyun
Park, Ha Young
Kwon, Mi Jung
author_sort Cho, Yoon Ah
collection PubMed
description Background: The prognostic relevance of the PIK3CA mutation together with PD-L1, c-Met, and mismatch repair deficiency (dMMR) have not been fully investigated in Asian women with breast cancer (BC) who have undergone postoperative adjuvant chemotherapy. Methods: We analyzed PIK3CA mutations via peptide nucleic acid (PNA)-mediated real-time PCR assay, PD-L1/c-Met expression via immunohistochemistry (IHC), and microsatellite instability (MSI) status using PCR and IHC, in 191 resected BCs from 2008 to 2011. The Cancer Genome Atlas (TCGA) dataset for the involvement of the PIK3CA mutation with PD-L1/c-Met/MMR was explored. Results: The PNA clamp-mediated assay was able to detect the PIK3CA mutation in 1% of the mutant population in the cell line validation. Using this method, the PIK3CA mutation was found in 78 (49.4%) of 158 samples. c-Met and PD-L1 positivity were identified in 31.4 and 21.8% of samples, respectively, which commonly correlated with high histologic grade and triple-negative subtype. MSI/dMMR was observed in 8.4% of patients, with inconsistency between MMR IHC and the MSI PCR. The PIK3CA mutation exhibited a poor prognostic association regarding recurrence-free survival (RFS) in both overall and triple-negative BCs. In subgroup analyses, the PIK3CA-mutated tumors showed poorer RFS than the PIK3CA-wildtype within the c-Met-positive, MSS, triple-negative, or age onset <50 years subgroups, which showed a similar trend of association in TCGA data. Conclusions: PIK3CA mutation together with c-Met or dMMR/MSI status might be relevant to poor prognosis in BC subsets, especially in Asian women.
format Online
Article
Text
id pubmed-9140087
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-91400872022-05-28 PIK3CA Mutation as Potential Poor Prognostic Marker in Asian Female Breast Cancer Patients Who Received Adjuvant Chemotherapy Cho, Yoon Ah Ko, Seung Yeon Suh, Yong Joon Kim, Sanghwa Park, Jung Ho Park, Hye-Rim Seo, Jinwon Choi, Hyo Geun Kang, Ho Suk Lim, Hyun Park, Ha Young Kwon, Mi Jung Curr Oncol Article Background: The prognostic relevance of the PIK3CA mutation together with PD-L1, c-Met, and mismatch repair deficiency (dMMR) have not been fully investigated in Asian women with breast cancer (BC) who have undergone postoperative adjuvant chemotherapy. Methods: We analyzed PIK3CA mutations via peptide nucleic acid (PNA)-mediated real-time PCR assay, PD-L1/c-Met expression via immunohistochemistry (IHC), and microsatellite instability (MSI) status using PCR and IHC, in 191 resected BCs from 2008 to 2011. The Cancer Genome Atlas (TCGA) dataset for the involvement of the PIK3CA mutation with PD-L1/c-Met/MMR was explored. Results: The PNA clamp-mediated assay was able to detect the PIK3CA mutation in 1% of the mutant population in the cell line validation. Using this method, the PIK3CA mutation was found in 78 (49.4%) of 158 samples. c-Met and PD-L1 positivity were identified in 31.4 and 21.8% of samples, respectively, which commonly correlated with high histologic grade and triple-negative subtype. MSI/dMMR was observed in 8.4% of patients, with inconsistency between MMR IHC and the MSI PCR. The PIK3CA mutation exhibited a poor prognostic association regarding recurrence-free survival (RFS) in both overall and triple-negative BCs. In subgroup analyses, the PIK3CA-mutated tumors showed poorer RFS than the PIK3CA-wildtype within the c-Met-positive, MSS, triple-negative, or age onset <50 years subgroups, which showed a similar trend of association in TCGA data. Conclusions: PIK3CA mutation together with c-Met or dMMR/MSI status might be relevant to poor prognosis in BC subsets, especially in Asian women. MDPI 2022-04-19 /pmc/articles/PMC9140087/ /pubmed/35621626 http://dx.doi.org/10.3390/curroncol29050236 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Cho, Yoon Ah
Ko, Seung Yeon
Suh, Yong Joon
Kim, Sanghwa
Park, Jung Ho
Park, Hye-Rim
Seo, Jinwon
Choi, Hyo Geun
Kang, Ho Suk
Lim, Hyun
Park, Ha Young
Kwon, Mi Jung
PIK3CA Mutation as Potential Poor Prognostic Marker in Asian Female Breast Cancer Patients Who Received Adjuvant Chemotherapy
title PIK3CA Mutation as Potential Poor Prognostic Marker in Asian Female Breast Cancer Patients Who Received Adjuvant Chemotherapy
title_full PIK3CA Mutation as Potential Poor Prognostic Marker in Asian Female Breast Cancer Patients Who Received Adjuvant Chemotherapy
title_fullStr PIK3CA Mutation as Potential Poor Prognostic Marker in Asian Female Breast Cancer Patients Who Received Adjuvant Chemotherapy
title_full_unstemmed PIK3CA Mutation as Potential Poor Prognostic Marker in Asian Female Breast Cancer Patients Who Received Adjuvant Chemotherapy
title_short PIK3CA Mutation as Potential Poor Prognostic Marker in Asian Female Breast Cancer Patients Who Received Adjuvant Chemotherapy
title_sort pik3ca mutation as potential poor prognostic marker in asian female breast cancer patients who received adjuvant chemotherapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9140087/
https://www.ncbi.nlm.nih.gov/pubmed/35621626
http://dx.doi.org/10.3390/curroncol29050236
work_keys_str_mv AT choyoonah pik3camutationaspotentialpoorprognosticmarkerinasianfemalebreastcancerpatientswhoreceivedadjuvantchemotherapy
AT koseungyeon pik3camutationaspotentialpoorprognosticmarkerinasianfemalebreastcancerpatientswhoreceivedadjuvantchemotherapy
AT suhyongjoon pik3camutationaspotentialpoorprognosticmarkerinasianfemalebreastcancerpatientswhoreceivedadjuvantchemotherapy
AT kimsanghwa pik3camutationaspotentialpoorprognosticmarkerinasianfemalebreastcancerpatientswhoreceivedadjuvantchemotherapy
AT parkjungho pik3camutationaspotentialpoorprognosticmarkerinasianfemalebreastcancerpatientswhoreceivedadjuvantchemotherapy
AT parkhyerim pik3camutationaspotentialpoorprognosticmarkerinasianfemalebreastcancerpatientswhoreceivedadjuvantchemotherapy
AT seojinwon pik3camutationaspotentialpoorprognosticmarkerinasianfemalebreastcancerpatientswhoreceivedadjuvantchemotherapy
AT choihyogeun pik3camutationaspotentialpoorprognosticmarkerinasianfemalebreastcancerpatientswhoreceivedadjuvantchemotherapy
AT kanghosuk pik3camutationaspotentialpoorprognosticmarkerinasianfemalebreastcancerpatientswhoreceivedadjuvantchemotherapy
AT limhyun pik3camutationaspotentialpoorprognosticmarkerinasianfemalebreastcancerpatientswhoreceivedadjuvantchemotherapy
AT parkhayoung pik3camutationaspotentialpoorprognosticmarkerinasianfemalebreastcancerpatientswhoreceivedadjuvantchemotherapy
AT kwonmijung pik3camutationaspotentialpoorprognosticmarkerinasianfemalebreastcancerpatientswhoreceivedadjuvantchemotherapy